Excelsior Biopharma (TWO:6496) — Stock Price
Excelsior Biopharma (TWO:6496) is currently trading at NT$24.15 TWD, down 0.82% today. Over the past 52 weeks, shares have ranged between NT$22.85 and NT$30.20. This page tracks Excelsior Biopharma's live share price on the TWO exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. For company valuation and market capitalisation context, see Excelsior Biopharma market cap and net worth.
Excelsior Biopharma (6496) Stock Price Chart — Daily History & Trading Volume
The chart below tracks Excelsior Biopharma's daily closing share price and trading volume on the TWO exchange over the past year, giving a clear view of recent price momentum and liquidity.
Excelsior Biopharma Income Statement — Revenue, Profit & Earnings by Year
Excelsior Biopharma's annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Revenue | NT$898.26 Million | NT$861.91 Million | NT$771.56 Million | NT$671.76 Million | NT$1.34 Billion |
| Cost of Revenue | NT$538.10 Million | NT$479.81 Million | NT$464.63 Million | NT$384.59 Million | NT$1.05 Billion |
| Gross Profit | NT$360.17 Million | NT$382.10 Million | NT$306.93 Million | NT$287.17 Million | NT$293.35 Million |
| Research & Development | NT$96.09 Million | NT$83.62 Million | NT$62.51 Million | NT$42.32 Million | NT$56.00 Million |
| SG&A | NT$438.24 Million | NT$377.21 Million | NT$124.60 Million | NT$105.34 Million | NT$101.05 Million |
| Total Operating Expenses | NT$1.07 Billion | NT$940.64 Million | NT$387.08 Million | NT$320.13 Million | NT$297.65 Million |
| Operating Income | NT$-174.16 Million | NT$-78.73 Million | NT$-74.61 Million | NT$-25.32 Million | NT$-1.02 Million |
| EBITDA | — | — | NT$-28.39 Million | NT$745.00K | NT$27.63 Million |
| EBIT | — | — | NT$-74.61 Million | NT$-25.32 Million | NT$-1.02 Million |
| Interest Expense | NT$7.76 Million | NT$8.02 Million | NT$6.37 Million | NT$4.35 Million | NT$4.54 Million |
| Income Before Tax | NT$-172.34 Million | NT$-87.39 Million | NT$-81.95 Million | NT$-25.99 Million | NT$-10.03 Million |
| Income Tax Expense | — | — | NT$9.06 Million | NT$7.76 Million | NT$5.62 Million |
| Net Income | NT$-183.17 Million | NT$-98.70 Million | NT$-91.01 Million | NT$-33.76 Million | NT$-15.65 Million |
Excelsior Biopharma Balance Sheet — Assets, Liabilities & Shareholder Equity
The balance sheet below summarizes Excelsior Biopharma's financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Assets | NT$1.48 Billion | NT$1.58 Billion | NT$1.58 Billion | NT$1.71 Billion | NT$1.84 Billion |
| Total Current Assets | NT$726.24 Million | NT$773.70 Million | NT$984.09 Million | NT$1.44 Billion | NT$1.53 Billion |
| Cash & Equivalents | — | — | — | — | — |
| Short-term Investments | — | NT$11.45 Million | — | NT$211.19 Million | — |
| Net Receivables | NT$231.30 Million | NT$182.93 Million | NT$162.73 Million | NT$137.98 Million | NT$214.51 Million |
| Inventory | NT$285.18 Million | NT$302.93 Million | NT$217.28 Million | NT$188.58 Million | NT$204.60 Million |
| Property, Plant & Equipment | — | — | — | NT$164.61 Million | NT$188.08 Million |
| Goodwill | — | — | — | — | — |
| Total Liabilities | NT$679.78 Million | NT$586.89 Million | NT$472.87 Million | NT$507.53 Million | NT$608.90 Million |
| Total Current Liabilities | NT$371.60 Million | NT$225.77 Million | NT$166.28 Million | NT$458.64 Million | NT$250.27 Million |
| Long-term Debt | NT$110.00 Million | NT$110.00 Million | NT$0.00 | NT$0.00 | NT$293.99 Million |
| Net Debt | NT$106.42 Million | — | NT$-212.51 Million | NT$-519.44 Million | NT$-705.57 Million |
| Total Stockholder Equity | NT$804.23 Million | NT$991.45 Million | NT$1.10 Billion | NT$1.21 Billion | NT$1.23 Billion |
| Retained Earnings | NT$-93.41 Million | NT$89.70 Million | NT$186.94 Million | NT$278.19 Million | NT$307.42 Million |
Excelsior Biopharma Cash Flow Statement — Operating, Investing & Financing Activities
This cash flow statement breaks down how Excelsior Biopharma generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Cash Flow | NT$-138.72 Million | NT$-99.80 Million | NT$-134.75 Million | NT$5.49 Million | NT$55.82 Million |
| Capital Expenditures | NT$36.95 Million | NT$257.15 Million | NT$35.66 Million | NT$7.78 Million | NT$2.88 Million |
| Free Cash Flow | NT$-175.67 Million | NT$-356.95 Million | NT$-170.41 Million | NT$-2.30 Million | NT$52.95 Million |
| Investing Cash Flow | — | — | — | NT$-199.24 Million | NT$-10.68 Million |
| Financing Cash Flow | — | — | NT$-317.23 Million | NT$-13.73 Million | NT$-83.04 Million |
| Dividends Paid | — | — | — | — | NT$46.67 Million |
| Stock-Based Compensation | NT$282.00K | NT$331.00K | NT$262.00K | NT$37.00K | NT$0.00 |
| Depreciation | NT$71.68 Million | NT$70.96 Million | NT$46.22 Million | NT$26.06 Million | NT$28.65 Million |
| Change in Cash | NT$-54.74 Million | NT$-349.84 Million | NT$-305.36 Million | NT$-207.49 Million | NT$-37.90 Million |
Excelsior Biopharma Earnings History — EPS Actual vs. Analyst Estimates
Track Excelsior Biopharma's quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.
| Report Date | EPS Actual | EPS Estimate | Surprise |
|---|---|---|---|
| May 23, 2025 | — | — | — |
| May 31, 2023 | -0.52 | — | — |
| Mar 01, 2023 | -0.02 | — | — |
| Nov 30, 2022 | -0.22 | — | — |
| Aug 31, 2022 | -0.27 | — | — |
| May 10, 2022 | -0.22 | — | — |
| Mar 02, 2022 | -0.06 | — | — |
| Dec 01, 2021 | -0.27 | — | — |